VBS Molecular Diagnostics News
March 26, 2008 – Vascular BioSciences Awarded STTR Matching Grant from the State of North Carolina
January 24, 2008 – Vascular BioSciences Moves Research and Development to North Carolina
Chicago, Illinois, March 28, 2008 – Vascular BioSciences announced today that Abraham Rothman, M.D., will present experimental data on the use of Vascular BioSciencesí endoarterial biopsy catheter in models of pulmonary hypertension, lung transplant rejection, and congenital heart disease at the Society for Cardiovascular Angiography and Interventions annual scientific sessions at this yearís American College of Cardiology Annual Innovation in Intervention Meeting. Dr. Rothmanís presentation will be given from 3:00 to 4:00 pm at McCormick Place in Chicago, Illinois on March 30, 2008.
Dr. Rothman, a Professor of Pediatrics at the University of Nevada School of Medicine, and a Fellow of the American College of Cardiology, will present new techniques to assess pulmonary vascular gene expression, identify novel applications for existing drugs and describe new methods to deliver individualized pharmacogenomics for vascular diseases using endoarterial biopsy.
About Vascular BioSciences
Vascular BioSciences, a diversified biomedical company based in Research Triangle, North Carolina, provides solutions for vascular–based diseases in order to enhance and prolong human life.
Vascular BioSciences makes interventional catheters to obtain endoarterial biopsies, provides diagnostic services, and advances therapies in order to improve outcomes for vascular–based disease patients. More information is available at www.vascularbiosciences.com.
Durham, North Carolina, March 26, 2008 – Vascular BioSciences announced today it has been awarded a $100,000 STTR matching grant under the One North Carolina SBIR/STTR Matching Funds Program. The One North Carolina SBIR/STTR Matching Grant matches a recently awarded NIH Phase 1 STTR grant “Targeting Pulmonary Hypertension with R-Ras.”
David Mann, CEO of Vascular BioSciences commented, “This matching grant from the State of North Carolina will enable our company to expand our innovative product pipeline and to accelerate our commercialization efforts. I’d like to especially acknowledge the assistance and support of Governor Mike Easley, Congressman David Price, State Senator Floyd McKissick, Jr., State Representative Henry Michaux, Jr., the North Carolina Office of Science and Technology, and the North Carolina Department of Commerce.”
About Vascular BioSciences
Vascular BioSciences, a diversified biomedical company based in Research Triangle, North Carolina, provides solutions for vascular–based diseases in order to enhance and prolong human life.
Vascular BioSciences makes interventional catheters to obtain endoarterial biopsies, provides diagnostic services, and advances therapies in order to improve outcomes for vascular–based disease patients. More information is available at www.vascularbiosciences.com.
Durham, North Carolina, January 24, 2008 – Vascular BioSciences announced today that it has opened an office in Research Triangle, North Carolina that will be the principal location of the company’s research and development efforts.
The Research Triangle office will be the headquarters for the company’s interventional, molecular diagnostic, and therapeutic research and development pursuits. The company’s San Diego office will continue to serve as the coordinating facility for West Coast academic and corporate collaborations.
David Mann, CEO and Chairman of Vascular BioSciences, commented, “The Research Triangle area of North Carolina is one of the largest biotechnology hubs in the world and offers numerous opportunities to work closely with many outstanding academic institutions and corporate partners. As research and development is the current principal activity of the company, we look forward to further advancing these efforts through this strategic relocation.”
About Vascular BioSciences
Vascular BioSciences provides solutions for vascular-based diseases in order to enhance and prolong human life.
Vascular BioSciences makes interventional catheters to obtain endoarterial biopsies, provides diagnostic services, and advances therapies in order to improve outcomes for vascular-based disease patients. More information is available at www.vascularbiosciences.com.
San Diego, Calif., October 12, 2007 – Vascular BioSciences announced today that Dr. Roy Williams, Ph.D., will join the company as a Special Consultant for Bioinformatics. Dr. Williams brings extensive expertise in bioinformatics and microarray analysis to the companyís Molecular Diagnostics division.
Dr. Roy Williams, Ph.D., an experienced research scientist at the Burnham Institute for Medical Research, is an internationally recognized pioneer in genomics, microarray technology, and the computer based analysis of complex genome-wide datasets. Prior to joining the Burnham Institute, Dr. Williams was an important member of the Small Molecule Drug Discovery Group at Diversa Corp in San Diego, CA. Dr. Williams, who received his Ph.D. in Biochemistry from the University of Birmingham, United Kingdom, performed ground-breaking gene expression post-doctoral research at Stanford University, the University of Chicago, and the Pasteur Institute in Paris, France.
David Mann, CEO and Chairman of Vascular BioSciences, commented, “Dr. Williams is a brilliant scientist and a pleasure to work with. He provides the company with the necessary expertise to handle the large amounts of data generated in our analysis of endoarterial biopsy samples. Roy’s valuable skill set will greatly accelerate our efforts to provide personalized medicine to patients based on the molecular analysis of endoarterial biopsies. Roy will also be invaluable to our drug discovery efforts at VBS Pharmaceuticals.”
About Vascular BioSciences & VBS Pharmaceuticals
Vascular BioSciences, a diversified biomedical company based in San Diego, California, provides solutions for vascular-based diseases in order to enhance and prolong human life.
Vascular BioSciences makes interventional catheters to obtain endoarterial biopsies, provides diagnostic services, and advances therapies in order to improve outcomes for vascular-based disease patients.
For more information please visit: www.vascularbiosciences.com.
A newly formed majority-owned subsidiary, VBS Pharmaceuticals, has been created to provide a framework for Vascular Biosciences to engage in drug discovery and pharmaceutical development targeting vascular-based diseases.
For more information please visit: www.vbspharma.com.
Family of Companies
